Plus a must-read paper on what the IRA will do to formularies, and how that will impact patients
And the government is going to pay $85 or so for the new COVID-19 vaccines
And how tens of billions in 340B drug sales hinges on the definition of 'patient'
And a reminder: we could get some judicial action in an IRA case this week
Plus a brief detour to talk about how drugmakers disclose population size for new meds
And PhRMA has a new judge and AZ has a 'target date' for a decision in its case
Plus the early rumblings on how a shutdown with impact health policy
And elevating an interesting ICER gene therapy review that is flying below the radar
And almost everyone you can imagine just filed amicus briefs in the Merck IRA case
Plus lots of lots of polling that underscores why "Medicare negotiations" will be the "lockbox" of 2024
Plus a lawsuit story worth your time and a Regeneron quote to ponder
And a quick roundup of all the IRA legal news that seems to be falling between the cracks
